Cantor Fitzgerald Upgrades Capricor Therapeutics (CAPR) to Overweight

August 14, 2026 2:50 AM

Cantor Fitzgerald analyst Kristen Kluska upgraded Capricor Therapeutics (NASDAQ: CAPR) from Neutral to Overweight with a price target of $28.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found